Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Radix Astragali, the dried root of *Astragalus membranaceus* or *Astragalus mongholicus*, is a prominent herb in Traditional Chinese Medicine (TCM) known as Huangqi. It contains a variety of bioactive compounds, including astragalosides (saponins), flavonoids, and polysaccharides. In clinical settings, it is being evaluated for its ability to induce fetal hemoglobin (HbF) synthesis in non-transfusion-dependent beta-thalassemia patients, which may help improve anemia. Additionally, it has been studied for its role in modulating P-glycoprotein (P-gp) mediated drug transport and for its hypoglycemic effects in patients with pre-diabetes and type 2 diabetes mellitus. The herb is recognized for its immunomodulatory, antioxidant, and renoprotective properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on radix astragali.